PlainRecalls
FDA Drug Critical Class I Terminated

Vistide (cidofovir) Injection, 375 mg (75 mg/mL), 5 mL single-use vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, UPC 3 61958 01011 5; NDC 61958-0101-1.

Reported: May 22, 2013 Initiated: January 31, 2013 #D-324-2013

Product Description

Vistide (cidofovir) Injection, 375 mg (75 mg/mL), 5 mL single-use vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, UPC 3 61958 01011 5; NDC 61958-0101-1.

Reason for Recall

Presence of Particulate Matter: Particulate matter was found in some vials of Vistide (cidofovir injection).

Details

Recalling Firm
Gilead Sciences, Inc.
Units Affected
3,181 vials
Distribution
Nationwide in USA, Canada, and UK (Gilead facility in Cork Ireland). Cork facility distributed to Germany/Austria, Italy and Spain.
Location
Foster City, CA

Frequently Asked Questions

What product was recalled?
Vistide (cidofovir) Injection, 375 mg (75 mg/mL), 5 mL single-use vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, UPC 3 61958 01011 5; NDC 61958-0101-1.. Recalled by Gilead Sciences, Inc.. Units affected: 3,181 vials.
Why was this product recalled?
Presence of Particulate Matter: Particulate matter was found in some vials of Vistide (cidofovir injection).
Which agency issued this recall?
This recall was issued by the FDA Drug on May 22, 2013. Severity: Critical. Recall number: D-324-2013.